Therefore, PD-1/PD-L1-targeted immune checkpoint inhibitors have been approved for the treatment of advanced melanoma, kidney cancer, head and neck cancer, and non-small cell lung cancer (25). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.